Linsitinib (OSI-906)

Catalog No.S1091

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Cited by 49 Publications

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nature, 2016, 539(7630):570-574

PubMed: 27820945 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )
Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )
Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	NWnFTlNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMEK4NFYh\|ryP	MXTTRW5ITVJ?
KS-1	NFXJS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnzTWM2OD1yLkCzPFM2KM7:TR?=	MoPKV2FPT0WU
TE-11	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX4OFNKSzVyPUCuNFc5OjJizszN	M2mx[nNCVkeHUh?=
EW-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vIe2lEPTB;MD6wPFU5PSEQvF2=	NF\5XnRUSU6JRWK=
HMV-II	NIDzXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXyWm5KSzVyPUCuNFg5PDZizszN	M4PuU3NCVkeHUh?=
COLO-205	M17B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMUC0OVQh\|ryP	NFP1SYFUSU6JRWK=
ES1	M2LHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonTTWM2OD1yLkGwOlk3KM7:TR?=	NYTBVm5wW0GQR1XS
GDM-1	M4PSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLNU5RYUUN3ME2wMlE{Pjd{IN88US=>	MXXTRW5ITVJ?
ML-2	NH7QV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMUW4PVYh\|ryP	MUjTRW5ITVJ?
Saos-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PnUmlEPTB;MD6xOlUzPiEQvF2=	MWfTRW5ITVJ?
NCI-H1355	M1G0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XzWmlEPTB;MD6xPFE{PSEQvF2=	Mmr1V2FPT0WU
G-401	M{DvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3XPFB5UUN3ME2wMlE5OjNizszN	MXrTRW5ITVJ?
EW-16	M{H5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHhNoVKSzVyPUCuNVg4PzdizszN	NGO2NpdUSU6JRWK=
EW-7	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwMUi4PFEh\|ryP	NEOxXmNUSU6JRWK=
NCI-H727	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXXTWM2OD1yLkG5O\|k1KM7:TR?=	MVfTRW5ITVJ?
LCLC-97TM1	NWHuPZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm5NGZKSzVyPUCuNlA6PTVizszN	NYfs[IVpW0GQR1XS
NCI-H650	NUGyR5p4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHuxSIVKSzVyPUCuNlE{QDRizszN	NHf2XZZUSU6JRWK=
NCI-H2122	NEjTdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly4TWM2OD1yLkKzNlk6KM7:TR?=	NYjobFNDW0GQR1XS
SK-N-DZ	NVHreVZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1W2WmlEPTB;MD6yN\|Y6QCEQvF2=	NE\wc\|hUSU6JRWK=
HT-29	NEi4PINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMkSyOFgh\|ryP	M4fESXNCVkeHUh?=
LB771-HNC	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMkW5NVUh\|ryP	MYTTRW5ITVJ?
HT-144	NIqybZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMk[xPVEh\|ryP	Mn7GV2FPT0WU
LAN-6	NYi3c5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMk[zOFgh\|ryP	NWXZeXE6W0GQR1XS
EW-18	NVrtdpRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknOTWM2OD1yLkK3NFAyKM7:TR?=	MUXTRW5ITVJ?
LS-1034	M3L6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMkexN\|Ih\|ryP	NWjsN4t1W0GQR1XS
EW-11	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHlUo9KSzVyPUCuNlg1OzJizszN	M1nYXHNCVkeHUh?=
SNU-C1	NV:yZnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMkmzNVMh\|ryP	NFm4O\|RUSU6JRWK=
RS4-11	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLPe2J2UUN3ME2wMlM{PzV6IN88US=>	NEG5NJRUSU6JRWK=
ES4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwNEGwN\|gh\|ryP	M4WyTnNCVkeHUh?=
COLO-320-HSR	NILmT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwNEGzOlgh\|ryP	M33TOnNCVkeHUh?=
NB10	NInPNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwNEW0N\|ch\|ryP	NHS3fJNUSU6JRWK=
BFTC-905	M{jGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3YTWM2OD1yLkS2O\|U5KM7:TR?=	MnrlV2FPT0WU
A375	M3rMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLXXpJKSzVyPUCuOFc3OTdizszN	NWH2ZWF6W0GQR1XS
SJRH30	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fDVWlEPTB;MD61NFgzOiEQvF2=	NHPD[XdUSU6JRWK=
NOS-1	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwNUKyOlch\|ryP	MXvTRW5ITVJ?
SIG-M5	NVz4NlltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HZTWlEPTB;MD61N\|U2PyEQvF2=	MUTTRW5ITVJ?
DOK	M2f2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmG4TWM2OD1yLkW1OkDPxE1?	MWfTRW5ITVJ?
NB69	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEf0eYhKSzVyPUCuOVgzPTdizszN	MlPjV2FPT0WU
SK-NEP-1	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3GdXo6UUN3ME2wMlYxOjN4IN88US=>	MXLTRW5ITVJ?
SK-MM-2	NEXtT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q4TGlEPTB;MD62OVQ6OSEQvF2=	NIXTfW9USU6JRWK=
NCI-H358	NGXYVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjyW2FZUUN3ME2wMlY4ODh{IN88US=>	NHzodVZUSU6JRWK=
RH-1	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwN{S4OVkh\|ryP	MYfTRW5ITVJ?
NH-12	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7ZTWM2OD1yLke2NFQ3KM7:TR?=	NH;aPWRUSU6JRWK=
TE-12	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LYUmlEPTB;MD63OlQ5PiEQvF2=	NF\P[5ZUSU6JRWK=
COLO-668	NH3ROohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnl[3hKSzVyPUCuPFQ3PjZizszN	NX[4S25pW0GQR1XS
PANC-08-13	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITCPYZKSzVyPUCuPFY{PzdizszN	MX3TRW5ITVJ?
HCC2998	NWL3d4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;mTWM2OD1yLki4NlY{KM7:TR?=	M1zlWXNCVkeHUh?=
ABC-1	NH7wdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jydWlEPTB;MD65NFM2OiEQvF2=	MlH5V2FPT0WU
ES6	MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXiVlhKSzVyPUCuPVExPjZizszN	MmnCV2FPT0WU
SNU-387	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwOUmzPVMh\|ryP	Ml:wV2FPT0WU
CMK	NEXBXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nOVWlEPTB;MD65PVkzQSEQvF2=	NXXNTpZLW0GQR1XS
SJSA-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\vNlRKSzVyPUGuNFM3PTNizszN	MnnzV2FPT0WU
SIMA	NV3zZpBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTFwME[4NlUh\|ryP	NGXzeFdUSU6JRWK=
ES3	NGnxeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFwMUKyPVch\|ryP	M4S3fnNCVkeHUh?=
IGROV-1	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\DTWlEPTB;MT6xOVQ1PCEQvF2=	MojtV2FPT0WU
MEL-JUSO	M1;ZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnpR5lKSzVyPUGuNVU4PTlizszN	NHfucW5USU6JRWK=
T84	MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULVSJRjUUN3ME2xMlIxQTF2IN88US=>	NYXub4RiW0GQR1XS
CAL-85-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjOTWM2OD1zLkKzNVM5KM7:TR?=	NFWzcWxUSU6JRWK=
RD	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmO5TWM2OD1zLkK2OFU2KM7:TR?=	MXjTRW5ITVJ?
TE-8	NXjJPFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYruWHpLUUN3ME2xMlMyPDZ{IN88US=>	NH;0RlRUSU6JRWK=
L-363	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;DOW1KSzVyPUGuN\|QzODhizszN	Ml75V2FPT0WU
EKVX	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTFwM{S1Olgh\|ryP	MoXBV2FPT0WU
SK-MEL-3	M{CzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTFwNEi1OVYh\|ryP	NHvJPVZUSU6JRWK=
TGBC24TKB	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXZdmRKSzVyPUGuOVAyQTNizszN	MWPTRW5ITVJ?
NCI-H1770	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTFwNUGxNVMh\|ryP	M3;EdnNCVkeHUh?=
HuH-7	NHH4dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPlTWM2OD1zLk[wNFk5KM7:TR?=	NGPMVmdUSU6JRWK=
HL-60	NVvUVm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml22TWM2OD1zLk[2PVI5KM7:TR?=	MUfTRW5ITVJ?
TE-1	M3f5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zs[WlEPTB;MT63NFk1PSEQvF2=	Ml\vV2FPT0WU
LC-2-ad	M4jsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPlTWM2OD1zLkezPFg4KM7:TR?=	NHXjdHpUSU6JRWK=
LB647-SCLC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHToTJpKSzVyPUGuO\|Y2QDNizszN	M{i0VXNCVkeHUh?=
NCI-H2171	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j3VmlEPTB;MT63O\|cyPiEQvF2=	MlPxV2FPT0WU
SK-PN-DW	M2TXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnjbGxKSzVyPUGuPVEzQThizszN	MYfTRW5ITVJ?
MC-IXC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHlb5VKSzVyPUGuPVg6QCEQvF2=	MUTTRW5ITVJ?
LS-513	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIGwV\|RKSzVyPUKuNFU{ODVizszN	NWnNUFI2W0GQR1XS
EW-3	NF:zb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M370W2lEPTB;Mj6wPVg1PCEQvF2=	M4jxeHNCVkeHUh?=
OPM-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTJwMUCyJO69VQ>?	MoW2V2FPT0WU
LP-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7SWm9KSzVyPUKuNlU5ODdizszN	M3OyT3NCVkeHUh?=
LU-134-A	M{DxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7qdpZKSzVyPUKuNlc4KM7:TR?=	MWrTRW5ITVJ?
CP66-MEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLXTWM2OD1{LkK5NFE1KM7:TR?=	NXjpZ4R{W0GQR1XS
HCC1143	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvndHNKSzVyPUKuOFU{PjhizszN	M{\KcHNCVkeHUh?=
LOXIMVI	NWXSSYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrCV2xKSzVyPUKuOlAzOSEQvF2=	MUHTRW5ITVJ?
TE-10	MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3y1RWlEPTB;Mj63NFg{QCEQvF2=	NFL0UZRUSU6JRWK=
NCI-H1882	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzQN\|RHUUN3ME2yMlc2OjJ5IN88US=>	NHX1RllUSU6JRWK=
CHP-126	Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFf3XYpKSzVyPUKuO\|Y{OTdizszN	Mlz4V2FPT0WU
NCI-H1623	NWSwNGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIS1VnNKSzVyPUKuPVIxOjRizszN	MWTTRW5ITVJ?
GB-1	M4jDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[xTWM2OD1{LkmzOFA1KM7:TR?=	MX;TRW5ITVJ?
RCC10RGB	M2fuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJwOUWyPFEh\|ryP	NG\i[mRUSU6JRWK=
NCI-H2141	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXroZXhFUUN3ME2yMlk3QDl4IN88US=>	MoH5V2FPT0WU
GI-ME-N	M{\vV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTNwMEC1OlUh\|ryP	MUHTRW5ITVJ?
NCI-H526	NV7FdIV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXhOIlKSzVyPUOuNFQxQDVizszN	Mlu5V2FPT0WU
NCI-H747	M4\xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17DWGlEPTB;Mz6wOFk6OiEQvF2=	M4nPSnNCVkeHUh?=
SNU-423	M3XHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULnXVJxUUN3ME2zMlIxOzF\|IN88US=>	NE\Reo9USU6JRWK=
A427	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTNwMkW2PVkh\|ryP	MmjxV2FPT0WU
CAL-12T	NFnKS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjGVpJKSzVyPUOuOFA4OTNizszN	NWTiR3lmW0GQR1XS
LU-99A	NFHCbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDxcpBKSzVyPUOuOFcyODVizszN	MXXTRW5ITVJ?
MS-1	NILhV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTRTWM2OD1\|LkWzOFI6KM7:TR?=	NELZemVUSU6JRWK=
SK-LU-1	MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK2eWxKSzVyPUOuO\|YzQTVizszN	MkjzV2FPT0WU
SW837	NY\WXpVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLRfnBKSzVyPUOuO\|Y{OzNizszN	NXjtZ41NW0GQR1XS
ES8	M4fWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfHbHlKSzVyPUOuPFM5PzdizszN	NFjCPJpUSU6JRWK=
MZ2-MEL	NWKwbIp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrpZmtWUUN3ME2zMlkzODh4IN88US=>	M1q0PXNCVkeHUh?=
TGW	NGm3W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTRwMEGzNVEh\|ryP	NVfzZoU3W0GQR1XS
GP5d	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\YblhyUUN3ME20MlA2OzZ{IN88US=>	NHi0VVdUSU6JRWK=
BB49-HNC	M3rGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moe1TWM2OD12LkG1NlE{KM7:TR?=	M13D[HNCVkeHUh?=
NB13	NGTJcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fEZmlEPTB;ND6yOlg5PyEQvF2=	NFvHcWJUSU6JRWK=
NTERA-S-cl-D1	M4TyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NImySXhKSzVyPUSuNlg3OTVizszN	M1vaZnNCVkeHUh?=
NCI-H1648	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTRwMkm4NVkh\|ryP	NG\hfIlUSU6JRWK=
LCLC-103H	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTRwM{KxPVUh\|ryP	Mm\tV2FPT0WU
LS-411N	NEP5UWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTRwNES4PFUh\|ryP	NHmxdYtUSU6JRWK=
NCI-H1092	NFzpWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTRwNEW2PFch\|ryP	MmPpV2FPT0WU
PANC-10-05	NIPLbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PkWWlEPTB;ND62PVg1KM7:TR?=	NFe3[pZUSU6JRWK=
DK-MG	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDv[pBKSzVyPUSuPFA6OzNizszN	NH\CdohUSU6JRWK=
OVCAR-5	M3vtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTRwOEGyNlYh\|ryP	MoT5V2FPT0WU
CAL-39	NVPyS4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTRwOEe2O{DPxE1?	M4DJZXNCVkeHUh?=
TE-441-T	NV;mVVNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEflU2RKSzVyPUSuPVA2OzdizszN	MVXTRW5ITVJ?
MOLT-16	M1T5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHS4N4lKSzVyPUSuPVUzPTNizszN	MVvTRW5ITVJ?
MCF7	NGLMN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\uUJhKSzVyPUWuNVQ2OTdizszN	MYTTRW5ITVJ?
CAPAN-1	M1PlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37xWGlEPTB;NT6yOVcxPyEQvF2=	M3zy[nNCVkeHUh?=
PSN1	NHH3dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTVwMkeyN\|Uh\|ryP	NUfCcmJzW0GQR1XS
NCI-H292	NGq0NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTVwM{CwOFQh\|ryP	MmHUV2FPT0WU
CPC-N	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;iU2hYUUN3ME21MlM6PDF7IN88US=>	NEPnXGZUSU6JRWK=
DoTc2-4510	NXv5NXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTVwNEWzO\|Eh\|ryP	M2P4bXNCVkeHUh?=
LB1047-RCC	M{HVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnSO3VKSzVyPUWuOVU6OzNizszN	NGrkRohUSU6JRWK=
MHH-ES-1	NVTwUoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTVwNUm5NFch\|ryP	MVjTRW5ITVJ?
NMC-G1	NU\MfWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTGTWM2OD13LkewNlI4KM7:TR?=	M4HDSXNCVkeHUh?=
SW1710	NImzcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWf0W\|RNUUN3ME21Mlc1PzVzIN88US=>	NXOxdWNSW0GQR1XS
YAPC	M1LQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTVwN{[yNFEh\|ryP	M{m1e3NCVkeHUh?=
22RV1	M1\tSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTVwOECwNVkh\|ryP	MWTTRW5ITVJ?
COLO-679	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fhRmlEPTB;NT64PFk1QCEQvF2=	M1fEd3NCVkeHUh?=
TCCSUP	M3HtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVztdZlTUUN3ME21Mlk{OjV7IN88US=>	NV;CT286W0GQR1XS
C2BBe1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\md2lEPTB;NT65N\|k4KM7:TR?=	M{m2c3NCVkeHUh?=
TE-15	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTZwME[2NFUh\|ryP	MnvGV2FPT0WU
SCLC-21H	NICyUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjlTWM2OD14LkGwPFQ{KM7:TR?=	NVyzfWNlW0GQR1XS
EoL-1-cell	M2HPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTZwMU[1OlMh\|ryP	MkmyV2FPT0WU
NKM-1	NHfYdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ztOGlEPTB;Nj6xOlcyKM7:TR?=	M1PUTXNCVkeHUh?=
NCI-H1304	NVPjTGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:5bmhKSzVyPU[uNlc1OjhizszN	M{\NU3NCVkeHUh?=
NB6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFW2WFNKSzVyPU[uNlk3OjJizszN	Mn;LV2FPT0WU
NALM-6	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz5cnJKSzVyPU[uN\|MzOyEQvF2=	MWPTRW5ITVJ?
NCI-H522	M1e3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfqW5ZKSzVyPU[uN\|M{ODZizszN	NFuwTJZUSU6JRWK=
MV-4-11	M2rR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoC5TWM2OD14LkO3NFc6KM7:TR?=	MnPkV2FPT0WU
LB2241-RCC	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn30TWM2OD14LkO4OlY4KM7:TR?=	MYDTRW5ITVJ?
NCI-H1417	NF:4emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\GOGlEPTB;Nj60NFg1PyEQvF2=	NEXiZo1USU6JRWK=
HT-1197	NETRc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTuTWM2OD14LkW3NVIzKM7:TR?=	M{PqT3NCVkeHUh?=
P30-OHK	NFfCVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTZwNkK3O{DPxE1?	M1jMdnNCVkeHUh?=
ALL-PO	NGTUcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DpO2lEPTB;Nj63NVkyPiEQvF2=	NUC3O5FYW0GQR1XS
OVCAR-4	M2KxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTZwN{W0NFUh\|ryP	MXLTRW5ITVJ?
HCC2157	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELFNVhKSzVyPU[uO\|c1PzVizszN	Mo[4V2FPT0WU
NCI-H838	NWC2[WY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTZwOU[0PUDPxE1?	NEO3ZYxUSU6JRWK=
NCI-H1299	M4TTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTZwOUewPUDPxE1?	NF\vNZRUSU6JRWK=
SW954	NUW3N5VxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkn3TWM2OD15LkKwNFY5KM7:TR?=	M2DRdHNCVkeHUh?=
NCI-H441	NYfYNmE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDNbHVKSzVyPUeuN\|QxPjVizszN	MWDTRW5ITVJ?
SK-MEL-2	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkftTWM2OD15LkS4N\|c{KM7:TR?=	MVLTRW5ITVJ?
KARPAS-45	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu5TWM2OD15Lk[1PVI6KM7:TR?=	Mli3V2FPT0WU
CAL-54	NXLyZ2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLkdWdKSzVyPUeuPFI6PzdizszN	MWXTRW5ITVJ?
KYSE-180	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HhPWlEPTB;Nz64PFk1OSEQvF2=	M1PmRXNCVkeHUh?=
NCI-H187	NHO1TopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rPPGlEPTB;Nz65OVk1PyEQvF2=	NXPxdlB1W0GQR1XS
RT-112	NFnuNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlGyTWM2OD16LkC5Olc4KM7:TR?=	NW\6fVBKW0GQR1XS
NCI-H1437	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX70WYw4UUN3ME24MlA6Pzl3IN88US=>	NW\IZ5REW0GQR1XS
SNU-449	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7OW4N{UUN3ME24MlI5Ojd{IN88US=>	NVi4NI5UW0GQR1XS
HCC1187	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRThwMkmzPVEh\|ryP	NYnvbZlSW0GQR1XS
NCI-H2030	M1rzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLPTWM2OD16LkO3O\|E1KM7:TR?=	MnXUV2FPT0WU
HuO-3N1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PVR2lEPTB;OD6zO\|g1PCEQvF2=	Ml7uV2FPT0WU
COLO-792	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHSb\|BKSzVyPUiuOFE2OjdizszN	MkfoV2FPT0WU
MIA-PaCa-2	NVLSW5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTWS\|dKSzVyPUiuPFU2ODhizszN	MVPTRW5ITVJ?
SK-N-FI	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:4TWM2OD17LkC0NlUh\|ryP	MnLtV2FPT0WU
MMAC-SF	M4HTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGq3XpFKSzVyPUmuNFk4PTFizszN	M3PM[3NCVkeHUh?=
NCI-H28	NGfkb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrGTWM2OD17LkGwOFY6KM7:TR?=	MYfTRW5ITVJ?
ETK-1	NIn1XZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2K3PGlEPTB;OT6yPVk4PCEQvF2=	M4Hl[XNCVkeHUh?=
NCI-H1993	NXzm[nNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrHVlJKSzVyPUmuOFQzPjFizszN	NHywTXlUSU6JRWK=
no-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnH3TWM2OD17LkS3NVIh\|ryP	M3HYU3NCVkeHUh?=
ChaGo-K-1	NHzLbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjDfFVlUUN3ME25MlUyPTh\|IN88US=>	NYjOZlB3W0GQR1XS
NCCIT	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL6c41nUUN3ME25MlU{OTZ7IN88US=>	NWrmXppVW0GQR1XS
SAS	M4TobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnztTWM2OD1zMD6yOFgh\|ryP	MW\TRW5ITVJ?
A673	NV6zUo4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHhXmI4UUN3ME2xNE4{PzB2IN88US=>	NX\SS3p[W0GQR1XS
NCI-H1522	NXjnb5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTFyLkO3NFch\|ryP	M{DiOnNCVkeHUh?=
NCI-H810	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTFyLkO5NFch\|ryP	NI\0dZNUSU6JRWK=
IST-MES1	NV\FR2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDBdVBCUUN3ME2xNE41PTZ2IN88US=>	NIDrVYlUSU6JRWK=
GR-ST	NXnucnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HPfWlEPTB;MUCuOVAzPCEQvF2=	MXPTRW5ITVJ?
SUP-T1	MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTFyLkezNVch\|ryP	NFXFTY1USU6JRWK=
NB5	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFyLkmwNlIh\|ryP	NFLIdYZUSU6JRWK=
MZ1-PC	M2fxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTFyLkm1O\|Eh\|ryP	MX;TRW5ITVJ?
SK-CO-1	M2\kZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGKyZoRKSzVyPUGwMlk6OzFizszN	NGjCR2FUSU6JRWK=
Capan-2	M3W2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzn[JJNUUN3ME2xNU4{OTl6IN88US=>	M3\WSXNCVkeHUh?=
697	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\2TWM2OD1zMT62O\|U4KM7:TR?=	M12wW3NCVkeHUh?=
REH	NF3sUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF6wPGVKSzVyPUGxMlc1PTFizszN	NEfXVpVUSU6JRWK=
GI-1	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfWPJFKSzVyPUGxMlg3OTVizszN	MWTTRW5ITVJ?
BB65-RCC	NWPIOYk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTF{LkC5NVYh\|ryP	M4[5cnNCVkeHUh?=
NCI-H1651	M4rrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW1fI5KSzVyPUGyMlI1PzhizszN	NHvRdINUSU6JRWK=
NCI-H1618	NYHYfHVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFH2UnNKSzVyPUGyMlM6PzZizszN	MYDTRW5ITVJ?
NCI-H2081	NVH0Wll{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2W3fGlEPTB;MUKuOlE1OSEQvF2=	M3\Wd3NCVkeHUh?=
GCIY	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnftTWM2OD1zMj63NlE{KM7:TR?=	MnfjV2FPT0WU
NY	NFPqU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7Wc3B2UUN3ME2xN{4xPjR\|IN88US=>	NVH3TWVOW0GQR1XS
PANC-03-27	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;Cd3pKSzVyPUGzMlA5ODdizszN	M4DFTHNCVkeHUh?=
BHY	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTF\|LkKxNlEh\|ryP	MYrTRW5ITVJ?
SK-OV-3	MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTF\|LkO3OlMh\|ryP	Mo\2V2FPT0WU
5637	M2DCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfkTWM2OD1zMz63O\|U6KM7:TR?=	MUPTRW5ITVJ?
LC-1F	NV\RbW9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkS0TWM2OD1zND6wN\|U3KM7:TR?=	MV3TRW5ITVJ?
SNB75	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\4TWM2OD1zND6wN\|g{KM7:TR?=	Mo\iV2FPT0WU
CHP-212	NFPnOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTF2LkC0OlQh\|ryP	MXPTRW5ITVJ?
HT-1376	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nyZmlEPTB;MUSuNVEzPiEQvF2=	NHj3NJlUSU6JRWK=
MONO-MAC-6	NIXDVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPHTWM2OD1zND6xOVAzKM7:TR?=	M3;pTXNCVkeHUh?=
CA46	M3zJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTF2LkG4Nlch\|ryP	NGjM[mJUSU6JRWK=
SCC-15	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvWTWM2OD1zND61OVg{KM7:TR?=	MUfTRW5ITVJ?
ATN-1	NF;qbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjTeWN4UUN3ME2xOE43PjJ5IN88US=>	NEfqR4NUSU6JRWK=
NCI-H2405	NHKxd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG5TWM2OD1zND64NVU4KM7:TR?=	M3n4cHNCVkeHUh?=
NCI-H716	NFe5XYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[2dWpKSzVyPUG0Mlg1QTNizszN	NID1PHdUSU6JRWK=
SW620	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PCW2lEPTB;MUSuPVAyPCEQvF2=	MU\TRW5ITVJ?
NCI-H226	NEKycolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTF2LkmwPFUh\|ryP	NX\U[XRtW0GQR1XS
SW962	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{CzcWlEPTB;MUSuPVQ{OiEQvF2=	MkC5V2FPT0WU
KYSE-150	NUjE[GlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTF2Lkm1OUDPxE1?	MVjTRW5ITVJ?
OCUB-M	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3wTWM2OD1zND65PFg{KM7:TR?=	NWTKbIdlW0GQR1XS
ES7	Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoOxTWM2OD1zNT6wPVg1KM7:TR?=	NUjRR\|VuW0GQR1XS
SW1463	M{jmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVux[ZFuUUN3ME2xOU41OjJ\|IN88US=>	MVPTRW5ITVJ?
CAKI-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTF3LkWzOFYh\|ryP	NGfJV21USU6JRWK=
MKN28	NH\6OnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrRXJhMUUN3ME2xOU42PDd7IN88US=>	MVPTRW5ITVJ?
SW13	NFjvb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTF3Lk[xPEDPxE1?	M3zmeXNCVkeHUh?=
A3-KAW	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfuS3lKSzVyPUG1Mlk3QTdizszN	MVHTRW5ITVJ?
LU-65	NH3mcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3X0SWlEPTB;MUWuPVc3QCEQvF2=	NFyyTI1USU6JRWK=
Calu-1	NUTlcWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk[yTWM2OD1zNj6wN\|Y5KM7:TR?=	M1;XUHNCVkeHUh?=
ST486	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fncmlEPTB;MU[uNFQ{OSEQvF2=	NW\I[4djW0GQR1XS
BB30-HNC	NIXJUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELSXoFKSzVyPUG2MlEzPDZizszN	MoKzV2FPT0WU
EGI-1	NWjQbXlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHuTWM2OD1zNj60OFYh\|ryP	MWPTRW5ITVJ?
SH-4	M{nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFO3OI9KSzVyPUG2MlQ4OzFizszN	MX7TRW5ITVJ?
MN-60	NUnFT\|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LLSGlEPTB;MUeuNlI6PyEQvF2=	NXPQNXJiW0GQR1XS
MPP-89	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnGNodKSzVyPUG3MlI1PTlizszN	NGHCdpVUSU6JRWK=
A2780	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTF5LkSxN\|kh\|ryP	NHvYdFVUSU6JRWK=
Daoy	NWTDdG0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\abIRzUUN3ME2xO{41Pjl3IN88US=>	MlLnV2FPT0WU
NCI-H2126	NWC5R5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDtTWM2OD1zNz60O\|cyKM7:TR?=	NHzlbGZUSU6JRWK=
NCI-H1563	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPlcYFKSzVyPUG3MlQ6OTdizszN	NWTKOItrW0GQR1XS
8-MG-BA	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jY[GlEPTB;MUeuOlY1QCEQvF2=	NHy5eVRUSU6JRWK=
786-0	M{XEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXxVpdKSzVyPUG3Mlg{PTNizszN	NX7rRpkyW0GQR1XS
AM-38	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTqSlB5UUN3ME2xO{46OzB4IN88US=>	NInFOFlUSU6JRWK=
COLO-824	NIDDUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDoO412UUN3ME2xPE41PDN4IN88US=>	MlzhV2FPT0WU
SK-MEL-30	NYPUWlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTF6LkWwPFIh\|ryP	MkjqV2FPT0WU
CESS	NWj5U3FqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTF6Lke2NFkh\|ryP	M4fxOXNCVkeHUh?=
BL-70	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTF6LkixOVYh\|ryP	MWDTRW5ITVJ?
NCI-H2170	NWTzVnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTF6LkmxO\|kh\|ryP	NGHIOGRUSU6JRWK=
HT-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjtR4Z2UUN3ME2xPE46QDNizszN	NFTCb29USU6JRWK=
BOKU	NVrp[5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfpTWM2OD1zOT6wN\|gyKM7:TR?=	Mlu4V2FPT0WU
HPAF-II	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfWcGNKSzVyPUG5MlMxOTVizszN	Ml\jV2FPT0WU
KGN	NUPpSHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUi0foo2UUN3ME2xPU41PzZ3IN88US=>	M1r5PHNCVkeHUh?=
MC-CAR	NX3Bd2JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfEcHZKSzVyPUG5MlY{OTNizszN	MmjDV2FPT0WU
BHT-101	M1fLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTF7Lke3O{DPxE1?	M1[0W3NCVkeHUh?=
SW1783	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF7Lke4NFYh\|ryP	NWHSfmJsW0GQR1XS
KP-N-YN	M{LsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPPTWM2OD1{MD6wNlYzKM7:TR?=	MV7TRW5ITVJ?
LU-165	NVTEWZdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\PTWM2OD1{MD61OVcyKM7:TR?=	NUXJeodTW0GQR1XS
GOTO	M2jlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{G4UGlEPTB;MkCuOlQ2OSEQvF2=	NYDJVFg1W0GQR1XS
EFM-19	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33DcWlEPTB;MkGuNFcyPiEQvF2=	NW\lSY5UW0GQR1XS
CTV-1	NGPpWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfsSXE5UUN3ME2yNU4yODV2IN88US=>	NUHMc2pIW0GQR1XS
HEL	M{DvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJzLkSyNVYh\|ryP	MnW4V2FPT0WU
SNU-C2B	M{\jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTlTWM2OD1{MT60NlYh\|ryP	MkHrV2FPT0WU
ECC4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jncmlEPTB;MkGuO\|A4KM7:TR?=	NXXxRZFXW0GQR1XS
NEC8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1X5VWlEPTB;MkGuPFM3QCEQvF2=	NWDNUmpDW0GQR1XS
KMOE-2	NXrPWG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\GTWM2OD1{MT64PVIyKM7:TR?=	MkjwV2FPT0WU
NCI-H524	NYjEdm42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnq1TWM2OD1{Mj6wPFA5KM7:TR?=	NGHocnRUSU6JRWK=
WSU-NHL	NEHFXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XCTmlEPTB;MkKuNVU4PyEQvF2=	MVzTRW5ITVJ?
SF126	NYjBZ3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlm1TWM2OD1{Mj6yOFY6KM7:TR?=	NF7GW21USU6JRWK=
HOP-92	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTJ{LkOxOlch\|ryP	NIGzU\|VUSU6JRWK=
CTB-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrEbpdKSzVyPUKyMlQ3PzdizszN	NVK2O5BWW0GQR1XS
KYSE-270	NF\OcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTJ{LkmzOVch\|ryP	M3;Ub3NCVkeHUh?=
SK-MEL-24	M{fMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTJ\|LkG4O{DPxE1?	NXn1eYVRW0GQR1XS
Calu-3	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfqVGI4UUN3ME2yN{4zOTJ6IN88US=>	NIfGemNUSU6JRWK=
GAMG	M3vhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrITWM2OD1{Mz6yN\|Y4KM7:TR?=	M{HBfXNCVkeHUh?=
SW1573	M1S4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHtVXRQUUN3ME2yN{44PDF3IN88US=>	MlLKV2FPT0WU
MHH-NB-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PQcGlEPTB;MkSuNFE6PCEQvF2=	M3zYZXNCVkeHUh?=
TK10	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S2W2lEPTB;MkSuOVAyOyEQvF2=	Ml7qV2FPT0WU
LB373-MEL-D	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHN[JpKSzVyPUK0MlYxPjRizszN	M1rzUXNCVkeHUh?=
KALS-1	NGTzdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1L0OmlEPTB;MkSuO\|MzPyEQvF2=	MV\TRW5ITVJ?
HUTU-80	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PQS2lEPTB;MkWuPFA{OiEQvF2=	MWDTRW5ITVJ?
HuP-T3	NFPSW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDD[GRKSzVyPUK2MlE3PzRizszN	NFHhSHZUSU6JRWK=
OE19	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTJ4LkKxOVMh\|ryP	NITiNndUSU6JRWK=
J82	NWTBOHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\UbmJKSzVyPUK2MlI1PzFizszN	MYfTRW5ITVJ?
DU-4475	M3izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTJ4LkO4NVkh\|ryP	NIrqe\|BUSU6JRWK=
DMS-53	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLvTWM2OD1{Nj61NVM5KM7:TR?=	NHm3c2xUSU6JRWK=
COLO-741	Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;PNYVKSzVyPUK2Mlg{PDRizszN	MX\TRW5ITVJ?
SW48	M3vKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX4dGxTUUN3ME2yOk45QDJizszN	M162SnNCVkeHUh?=
IGR-1	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnRTWM2OD1{Nj65N\|M1KM7:TR?=	NIHGRZRUSU6JRWK=
639-V	NUPEOohST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHFTWM2OD1{Nz6wNlQ2KM7:TR?=	NHXrU4NUSU6JRWK=
LK-2	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDQWnUzUUN3ME2yO{41OTRzIN88US=>	NIfSU5VUSU6JRWK=
NCI-H2347	NYT5[Yw6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TrOGlEPTB;MkeuPVY6QSEQvF2=	Mn3oV2FPT0WU
NCI-H2228	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFP4OnlKSzVyPUK4MlA6ODVizszN	M4PWUnNCVkeHUh?=
LS-123	NWL2Z485T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jvR2lEPTB;MkiuNVI3OiEQvF2=	M4f6XnNCVkeHUh?=
U031	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVntRlNHUUN3ME2yPE4zPTJizszN	M3\TSXNCVkeHUh?=
NCI-H1792	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ6LkS3NlEh\|ryP	NGnpPJhUSU6JRWK=
NCI-H2087	MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD1[GFDUUN3ME2yPE44PTV{IN88US=>	NIjuO4lUSU6JRWK=
NCI-H2342	NGL6NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHJR3dzUUN3ME2yPU42OjB6IN88US=>	Mk\nV2FPT0WU
SW626	M13WbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTJ7Lke1OkDPxE1?	NGqwcVJUSU6JRWK=
LB2518-MEL	Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XNTmlEPTB;MkmuPFE2KM7:TR?=	NWP1cop5W0GQR1XS
RXF393	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\CTWM2OD1\|MD6wPVUzKM7:TR?=	MUnTRW5ITVJ?
LC4-1	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXOR2t5UUN3ME2zNE4{ODl{IN88US=>	M3i3dXNCVkeHUh?=
NCI-H1694	NUPpSmJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTNyLk[2NlQh\|ryP	MnLqV2FPT0WU
K5	M{DjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLoeXFKSzVyPUOwMlk4ODJizszN	MnvKV2FPT0WU
HDLM-2	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3CRmVKSzVyPUOwMlk4OjVizszN	MX7TRW5ITVJ?
BCPAP	NILPZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHRXWZKSzVyPUOxMlg{PzlizszN	NXi2[Vk2W0GQR1XS
BC-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlS5TWM2OD1\|Mj6xOFA{KM7:TR?=	Ml3zV2FPT0WU
LB996-RCC	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXs[29KSzVyPUOyMlI{PThizszN	NGLDPG1USU6JRWK=
NCI-H2009	M1vUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTN{LkS5PFEh\|ryP	NXvqfWFWW0GQR1XS
HTC-C3	NHG5SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rX[2lEPTB;M{OuO\|UyQSEQvF2=	NWn2Uo5OW0GQR1XS
LAMA-84	NFy4Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml33TWM2OD1\|ND60OFA4KM7:TR?=	M1[3ZnNCVkeHUh?=
CCRF-CEM	NInRbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFz1PJNKSzVyPUO0MlU4OTVizszN	NWHyenFYW0GQR1XS
AN3-CA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTN3LkC1Olgh\|ryP	MWDTRW5ITVJ?
NCI-H1734	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXHN2lKSzVyPUO1MlI2PjFizszN	M2TCc3NCVkeHUh?=
Ca-Ski	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3tTWM2OD1\|NT60NVAyKM7:TR?=	NXO5Z4RHW0GQR1XS
U-266	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTN3Lk[xNVQh\|ryP	NXPkSpF5W0GQR1XS
SBC-5	NVjVOnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjwbnRKSzVyPUO1Mlc4QDFizszN	NEL2SY5USU6JRWK=
GT3TKB	M1\WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;NeGlEPTB;M{euNVE2KM7:TR?=	NXHiZ3dnW0GQR1XS
MDA-MB-175-VII	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTN5LkKyOFgh\|ryP	M{\DWHNCVkeHUh?=
PFSK-1	M2HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYX0e\|hIUUN3ME2zO{4zPDN3IN88US=>	M2TufnNCVkeHUh?=
IMR-5	NUH0PGxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK1TIJKSzVyPUO3MlI1QDdizszN	MlXVV2FPT0WU
Daudi	M1LRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTN5LkO1PVch\|ryP	NUPiSJdRW0GQR1XS
A498	NWjQ[2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPWPYxKSzVyPUO3MlczOThizszN	M3XNT3NCVkeHUh?=
SCC-4	NF61PIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLKb2xNUUN3ME2zO{44QDR\|IN88US=>	NXrGZllNW0GQR1XS
COLO-680N	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTN6LkK4PFUh\|ryP	MnT0V2FPT0WU
SK-MES-1	Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTN6LkOyNVUh\|ryP	M2\DUHNCVkeHUh?=
SR	NHjCOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL0SJdOUUN3ME2zPE42PDl3IN88US=>	NHXkTotUSU6JRWK=
LNCaP-Clone-FGC	NIDWdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTN6LkW2N\|ch\|ryP	M{LG[3NCVkeHUh?=
SK-HEP-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTN6Lke4NlIh\|ryP	MXnTRW5ITVJ?
BPH-1	NHO0VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P1bmlEPTB;M{iuPFMzQSEQvF2=	NF71OHhUSU6JRWK=
NCI-H1755	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfROmhKSzVyPUO5MlU5OTdizszN	MmXGV2FPT0WU
LXF-289	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPLNnpKSzVyPUO5MlgxQDRizszN	M32zfXNCVkeHUh?=
SW1088	MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\WcmJKSzVyPUSwMlIyODdizszN	MWDTRW5ITVJ?
MOLT-4	NFnEW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkO1TWM2OD12MD6yPVAyKM7:TR?=	NFixZVZUSU6JRWK=
AsPC-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTRyLkS1PFMh\|ryP	NXXFboszW0GQR1XS
HOP-62	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe0U\|VKSzVyPUSwMlY2PjhizszN	MV\TRW5ITVJ?
A172	M{Pmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnVZ3RlUUN3ME20NE45PTFzIN88US=>	MnzCV2FPT0WU
SN12C	NFfCUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTRyLkmzPFUh\|ryP	MmXsV2FPT0WU
MDA-MB-231	M2fwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jKdWlEPTB;NECuPVg6QCEQvF2=	MUTTRW5ITVJ?
RPMI-2650	NXPBe\|dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXRTWM2OD12MT6xOVk{KM7:TR?=	NYiy[VdnW0GQR1XS
KYSE-140	NYW2PHJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\3VmlEPTB;NEGuPFEzOyEQvF2=	MXPTRW5ITVJ?
KINGS-1	M3fubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1n0SGlEPTB;NEKuOFY6PyEQvF2=	NVfrZ41YW0GQR1XS
HSC-3	NXLkOWhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrofJpKSzVyPUSyMlY3PjFizszN	MlrmV2FPT0WU
PC-14	MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LjWGlEPTB;NEOuNVg5OiEQvF2=	M17qcnNCVkeHUh?=
COR-L105	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzSeFZKUUN3ME20N{43PTB{IN88US=>	Mn3BV2FPT0WU
BE-13	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTR2LkKzO\|Eh\|ryP	MXHTRW5ITVJ?
NCI-H661	NFq3dIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHFSIRKSzVyPUS0MlI6PThizszN	NFzjO2tUSU6JRWK=
IST-MEL1	NVPvS4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfKdJF2UUN3ME20OE4{PTl7IN88US=>	MlzLV2FPT0WU
HCC1806	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7nS2lKSzVyPUS0MlU5PzNizszN	M2jjRnNCVkeHUh?=
COLO-800	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPMeXN1UUN3ME20OE45PDV\|IN88US=>	NH76Nm9USU6JRWK=
IST-SL2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVWyWJA1UUN3ME20OU4yOjR5IN88US=>	M2\wcHNCVkeHUh?=
8305C	NWj3dGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDJeWJKSzVyPUS1MlMxQSEQvF2=	NYS0fYlKW0GQR1XS
UACC-62	NGXlZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHyzTG5KSzVyPUS2MlI5PzVizszN	NHKzOoRUSU6JRWK=
COR-L23	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTR5LkG5PUDPxE1?	MVTTRW5ITVJ?
EFE-184	NX\5VZpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTwTWM2OD12Nz6zPFgh\|ryP	M2TUdnNCVkeHUh?=
DMS-114	NYPpZYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTR5LkSxOFkh\|ryP	NUnBPIdpW0GQR1XS
KYSE-520	NXHTfHk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnIOY1KSzVyPUS4MlU{OTVizszN	M2K2[XNCVkeHUh?=
SNG-M	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn4TWM2OD12OT60N\|Qh\|ryP	Ml3VV2FPT0WU
A2058	M{HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTR7LkS4PFUh\|ryP	NWTEcVluW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	+ Expand Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Formulation: 25 mM tartaric acid Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02057380	Completed	Advanced Solid Tumors	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	April 16 2014	Phase 2
NCT02057380	Completed	Advanced Solid Tumors	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	April 16 2014	Phase 2
NCT02546544	Completed	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT02546544	Completed	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01427205	Withdrawn	Head and Neck Cancer	M.D. Anderson Cancer Center\|OSI Pharmaceuticals	June 2013	Phase 2
NCT01427205	Withdrawn	Head and Neck Cancer	M.D. Anderson Cancer Center\|OSI Pharmaceuticals	June 2013	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products4

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324|Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)

Cited by 49 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Linsitinib (OSI-906) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)

Cited by 49 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Linsitinib (OSI-906) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)